Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04487860
Recruitment Status : Active, not recruiting
First Posted : July 27, 2020
Last Update Posted : June 27, 2022
Sponsor:
Information provided by (Responsible Party):
Sun Pharmaceutical Industries Limited

Brief Summary:
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study. I

Condition or disease Intervention/treatment Phase
Non-segmental Vitiligo Drug: AS012 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 327 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Actual Study Start Date : January 6, 2021
Actual Primary Completion Date : May 20, 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Vitiligo
MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Experimental: AS012 dose regimen I
Oral
Drug: AS012
oral administration

Experimental: AS012 dose regimen II
Oral
Drug: AS012
oral administration

Experimental: AS012 dose regimen III
Oral
Drug: AS012
oral administration

Experimental: AS012 dose regimen IV
Oral
Drug: AS012
oral administration

Placebo Comparator: Placebo
Oral
Drug: Placebo
oral administration




Primary Outcome Measures :
  1. Mean change from baseline in Vitiligo Area Scoring Index score [ Time Frame: Week 24 ]
    Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state


Secondary Outcome Measures :
  1. Mean change from baseline in Vitiligo Extent Score [ Time Frame: Week 24 ]
    Natural distribution of vitiligo on body reflecting 6 different degrees of involvement (1 percent, 5 percent, 10 percent, 25 percent, 50 percent, 75 percent).

  2. Mean change in Vitiligo Impact Patient scale [ Time Frame: Week 24 ]
    subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. Summary scores range from 0 to 100

  3. Physician's global assessment scores [ Time Frame: Week 52 ]
    Score 0=no involvement or Score 1=limited extent with at least 2-point reduction from baseline

  4. Mean change, from baseline, in Dermatology Life Quality Index [ Time Frame: Week 52 ]

    The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0.

    The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide written informed consent.
  2. Male or female ≥ 18 years of age at time of screening
  3. Stable (without new patches ≥ 1 year) or unstable (with new patches for the last 1 year) vitiligo
  4. VASI of ≥ 4 at screening and baseline

Exclusion Criteria:

  1. Segmental vitiligo, focal, or mixed Vitiligo
  2. Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment
  3. History of alcohol or drug abuse in the previous 2 years
  4. Subjects who were submitted to melanocyte transfer

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04487860


Locations
Show Show 28 study locations
Sponsors and Collaborators
Sun Pharmaceutical Industries Limited
Layout table for additonal information
Responsible Party: Sun Pharmaceutical Industries Limited
ClinicalTrials.gov Identifier: NCT04487860    
Other Study ID Numbers: AS012-20-01
First Posted: July 27, 2020    Key Record Dates
Last Update Posted: June 27, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases